Meyahealth
HomeGeneticsGeneNLRP12 gene
Back to Gene
NLRP12 gene
Reviewed by Medicinsk Expert•Last updated: 2026-10-22•Gene

NLRP12 gene

The NLRP12 gene provides instructions for making the monarch-1 protein, which plays a critical role in regulating the body's inflammatory response.

Normal Function

The NLRP12 gene provides instructions for making a protein called monarch-1, a member of the NOD-like receptor (NLR) protein family found primarily in certain white blood cells. These proteins help control the immune system's response to injury, toxins, or foreign invaders.

Monarch-1 is involved in inflammation—the process where the immune system sends signaling molecules and white blood cells to a site of injury or disease. While it can trigger inflammation when necessary, monarch-1 primarily functions to stop (inhibit) the inflammatory response to prevent damage to the body's own cells and tissues once the threat is addressed.

Health Conditions Related to Genetic Changes

Familial cold autoinflammatory syndrome type 2

At least 20 variants in the NLRP12 gene have been found to cause familial cold autoinflammatory syndrome type 2. This condition is characterized by episodes of fever, skin rash, and joint pain, often triggered by cold temperatures.

Most of these variants reduce the ability of monarch-1 to inhibit inflammation, leading to an unusually long inflammatory response. Some variants may also increase the protein's ability to trigger inflammation even in the absence of injury or disease. In some cases, individuals with a variant may not develop symptoms, a situation known as reduced penetrance.

Genomic Location

The NLRP12 gene is found on chromosome 19.

Frequently Asked Questions

Cold exposure is the most common trigger; even mild drops in ambient temperature can provoke an attack. Other triggers include stress, infections, and certain medications. Avoiding sudden temperature changes, wearing layered clothing in cold weather, and using a humidifier in dry environments can reduce flare frequency. Keeping a symptom diary helps identify personal triggers.
Diagnosis starts with a detailed clinical history and physical exam. Laboratory tests include a complete blood count showing elevated neutrophils, an ESR or CRP rise during flares, and a skin biopsy if rash is present. Genetic testing—usually a targeted NLRP12 sequencing panel—is required to identify pathogenic variants.
Yes. Even asymptomatic carriers can develop symptoms later, and early intervention can prevent joint damage and improve quality of life. Regular monitoring every 3–6 months, including symptom review and inflammatory markers, is recommended. Discuss with a rheumatologist whether low‑dose colchicine or an IL‑1 blocker might be appropriate.
Colchicine is often first‑line; it disrupts microtubule formation, reducing neutrophil activity and inflammation. If colchicine is ineffective or poorly tolerated, IL‑1 inhibitors such as anakinra or canakinumab are highly effective because they block the key cytokine driving the inflammatory cascade. Treatment response is monitored by symptom frequency, CRP/ESR levels, and patient‑reported outcomes.
Source: MedlinePlus, National Library of Medicine

MedlinePlus brings together authoritative health information from the National Library of Medicine (NLM), the National Institutes of Health (NIH), and other government agencies and health-related organizations.

Meyahealth

Ⓒ 2026. All rights reserved by MEYA

About UsTerms & PolicyFAQ